
Navidea Biopharmaceuticals, Inc. Releases Findings from Exploratory Analysis Conducted on July 2, 2024
Navidea Biopharmaceuticals, Inc. a company specializing in precision immunodiagnostic agents and immunotherapeutics, has disclosed disappointing findings from an exploratory analysis conducted on its pivotal NAV3-33 clinical trial, titled “Evaluation of…












